LianBio LIAN:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
2.40quote price arrow down-0.15 (-5.88%)
Volume
254,918
52 week range
2.10 - 16.37
Loading...
  • Open2.50
  • Day High2.60
  • Day Low2.36
  • Prev Close2.55
  • 52 Week High16.37
  • 52 Week High Date11/19/21
  • 52 Week Low2.10
  • 52 Week Low Date08/03/22

Key Stats

  • Market Cap260.04M
  • Shares Out108.35M
  • 10 Day Average Volume0.62M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-61.04

KEY STATS

  • Open2.50
  • Day High2.60
  • Day Low2.36
  • Prev Close2.55
  • 52 Week High16.37
  • 52 Week High Date11/19/21
  • 52 Week Low2.10
  • 52 Week Low Date08/03/22
  • Market Cap260.04M
  • Shares Out108.35M
  • 10 Day Average Volume0.62M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-61.04

RATIOS/PROFITABILITY

  • EPS (TTM)-0.98
  • P/E (TTM)-2.46
  • Fwd P/E (NTM)-1.57
  • EBITDA (TTM)-106.251M
  • ROE (TTM)-25,011.74%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date12/09/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On LianBio

There is no recent news for this security.

Profile

MORE
LianBio is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It offers a pipeline of nine product candidates across five therapeutic areas, namely cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib...
Konstantin Poukalov
Executive Chairman of the Board
Yizhe Wang Ph.D.
Chief Executive Officer, Director
Debra Yu M.D.
President, Chief Strategy Officer
Yi Larson
Chief Financial Officer
Address
103 Carnegie Center Drive
Suite 309, Suite 215
Princeton, NJ
08540
United States